V
41.69
0.12 (0.29%)
| Penutupan Terdahulu | 41.57 |
| Buka | 40.71 |
| Jumlah Dagangan | 474,170 |
| Purata Dagangan (3B) | 893,453 |
| Modal Pasaran | 3,295,559,936 |
| Harga / Pendapatan (P/E TTM) | 109.71 |
| Harga / Pendapatan (P/E Ke hadapan) | 27.78 |
| Harga / Jualan (P/S) | 6.73 |
| Harga / Buku (P/B) | 2.61 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | 7.13% |
| Margin Operasi (TTM) | 7.03% |
| EPS Cair (TTM) | 0.420 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 18.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.23% |
| Nisbah Semasa (MRQ) | 5.10 |
| Aliran Tunai Operasi (OCF TTM) | 89.42 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 76.93 M |
| Pulangan Atas Aset (ROA TTM) | 1.94% |
| Pulangan Atas Ekuiti (ROE TTM) | 2.86% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Menaik |
| Diagnostics & Research (Global) | Menaik | Menaik | |
| Stok | Veracyte, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.3
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.25 |
|
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.54% |
| % Dimiliki oleh Institusi | 107.98% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 50.00 (Guggenheim, 19.93%) | Beli |
| Median | 48.00 (15.14%) | |
| Rendah | 43.00 (Canaccord Genuity, 3.14%) | Pegang |
| Purata | 46.60 (11.78%) | |
| Jumlah | 3 Beli, 1 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 45.58 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 05 Jan 2026 | 50.00 (19.93%) | Beli | 43.63 |
| 05 Nov 2025 | 45.00 (7.94%) | Beli | 46.04 | |
| Morgan Stanley | 02 Dec 2025 | 48.00 (15.14%) | Jual | 46.16 |
| 11 Nov 2025 | 40.00 (-4.05%) | Jual | 42.66 | |
| Canaccord Genuity | 05 Nov 2025 | 43.00 (3.14%) | Pegang | 46.04 |
| Needham | 05 Nov 2025 | 44.00 (5.54%) | Beli | 46.04 |
| UBS | 05 Nov 2025 | 48.00 (15.14%) | Beli | 46.04 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 11 Jan 2026 | Pengumuman | Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results |
| 29 Dec 2025 | Pengumuman | Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 06 Nov 2025 | Pengumuman | Veracyte to Participate in Upcoming Investor Conferences |
| 04 Nov 2025 | Pengumuman | Veracyte Announces Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Pengumuman | Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |